This week, our CEO, Punit Dhillon, presented at the 15th Annual Rodman & Renshaw Global Investment Conference. The annual event hosted over 150 established and emerging biotech and pharmaceutical companies. During the presentation, Mr. Dhillon reviewed previous data points and provided an update on upcoming milestones. Here is an overview of the presentation:
In OncoSec’s active pursuit of knowledge in the cancer and biotech realms, we come across a vast number of articles that we believe exhibit strong signs of importance, within our industry. While we regularly share some of these with our online community, we would like to start highlighting certain news articles, study data, and other materials. Here are three articles we are currently reading:
The treatment of many cancer types can vary quite widely. Different cancers and stages denote slightly different methods of treatment. While the early stages of some cancers – especially skin cancer – can sometimes require only minor surgery, others can require highly damaging doses of radiation and chemotherapy. With immunotherapy, companies like OncoSec are hoping to increase the number of available cancer treatments that are less damaging to the body. One specific cancer that we’re targeting is Merkel cell carcinoma.
While skin cancer is well-known and well-documented, in most communities, few people differentiate between the various types. Melanoma, basal cell carcinoma and squamous cell carcinoma are, unfortunately, quite prevalent (and on the rise). It is important to understand the risk factors and preventative measures for these cancer types. However, there is one rare type of skin cancer called Merkel cell carcinoma: a deadly type of skin cancer with a low survival rate that still has no approved, specialized treatment method.
When researching and actively working towards the treatment of an emerging condition, it is important to pay close attention to the history of the disease and how it might help move forward the field of study and public awareness. Being a lesser-known form of cancer, Merkel cell carcinoma (MCC) has not been paid as close attention as its mortality rate should merit. At OncoSec, we believe that it is of high importance to advance the field of study surrounding MCC and to create a more effective treatment regimen.